Drug intelligence / Profile preview

GT20(x)

Development stage: Preclinical
Lead developer: Grid Therapeutics
Modality: Antibody-Based Therapeutics

Overview

GT20(x) is an investigational antibody-based drug initially developed by Grid Therapeutics LLC. It is being explored for the treatment of neoplasms, with a primary active indication in lung cancer. The drug's mechanism of action and specific target are not publicly detailed in available sources, but it is classified as an antibody therapeutic. Its highest global R&D status is preclinical, and it has also been considered for respiratory diseases[1].

Beyond the preview

Go deeper on GT20(x).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT20(x).

Explore the full profile